8-K: Tonix Pharmaceuticals Announces Publication of TNX-102 SL Research in Psychiatry Research

Tonix Pharmaceuticals announced the publication of a research paper showing nominal improvement in PTSD symptoms and sleep quality with TNX-102 SL in military-related PTSD after four weeks of treatment.

Summary

• Tonix Pharmaceuticals has announced the publication of a research paper in Psychiatry Research regarding their TNX-102 SL product.
• The study, a Phase 3 trial, evaluated the efficacy and safety of bedtime sublingual cyclobenzaprine (TNX-102 SL) in military-related posttraumatic stress disorder (PTSD).
• The research found that TNX-102 SL was well-tolerated and showed nominal improvement in PTSD severity and sleep quality measures within the first four weeks of treatment.
• The company believes these findings suggest a potential role for short-term bedtime TNX-102 SL treatment in the immediate aftermath of traumatic events.
• The data also supports a U.S. Department of Defense (DoD)-funded Phase 2 trial (OASIS) to evaluate TNX-102 SL in reducing acute stress reaction (ASR) and preventing acute stress disorder (ASD) and PTSD after civilian motor vehicle collisions.
• The OASIS trial is expected to begin enrolling in the second quarter and will test 14 days of bedtime TNX-102 SL 5.6 mg within 24 hours of a motor vehicle collision.
• TNX-102 SL is also in late-stage development for the management of fibromyalgia, with a New Drug Application (NDA) submission planned for the second half of 2024.

Sentiment

Score: 5

Explanation: The document presents mixed results. While there is positive news about the publication and the potential of TNX-102 SL, the failure to meet the primary endpoint in the Phase 3 study and previous trials tempers the overall sentiment. The upcoming OASIS trial and NDA submission for fibromyalgia are positive developments, but the risks associated with drug development remain.

Positives

• TNX-102 SL showed nominal improvement in PTSD severity and sleep quality within four weeks of treatment.
• The drug was well-tolerated in the study, with no new safety signals observed.
• The company has a U.S. Department of Defense grant to support further research into TNX-102 SL for acute stress reaction and PTSD.
• The company is progressing with the development of TNX-102 SL for fibromyalgia, with an NDA submission planned for the second half of 2024.
• The company has a strong patent portfolio for TNX-102 SL, with market exclusivity expected until 2034/2035 for fibromyalgia.

Negatives

• The Phase 3 HONOR study did not reach statistical significance on the primary endpoint of improvement in PTSD symptoms at week 12.
• The improvement in PTSD symptoms and sleep quality was not sustained beyond week 4 in the HONOR study.
• Previous Phase 2 and Phase 3 trials of TNX-102 SL in PTSD did not reach statistical significance on the primary endpoint.

Risks

• The company faces risks related to obtaining FDA clearances or approvals for its products.
• There are risks related to the successful marketing of any of their products.
• The company faces risks related to the timing and progress of clinical development of their product candidates.
• The company may require additional financing.
• There are uncertainties of patent protection and litigation.
• There are uncertainties of government or third party payor reimbursement.
• The company has limited research and development efforts and dependence upon third parties.
• The company faces substantial competition.

Future Outlook

Tonix plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in the second half of 2024 for Tonmya for the management of fibromyalgia. The company also plans to begin enrolling patients in the OASIS trial in the second quarter.

Management Comments

• Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, stated that there is an urgent need for interventions to reduce rates of ASD and PTSD in the immediate aftermath of trauma.
• Seth Lederman, M.D., believes the results in the published paper suggest that bedtime TNX-102 SL has short-term activity on improving PTSD symptom severity and sleep quality in military-related PTSD.
• Dr. Gregory Sullivan, Chief Medical Officer of Tonix, said that sleep disturbances are known to play a critical role in the development and maintenance of PTSD.
• Dr. Gregory Sullivan also stated that the upcoming OASIS trial will test a 14-day short-course of bedtime TNX-102 SL therapy beginning within 24 hours of index trauma for effects on ASR symptoms and incidence of PTSD development.

Industry Context

The announcement is relevant to the broader pharmaceutical industry's focus on developing treatments for mental health conditions, particularly PTSD and fibromyalgia. The company is also leveraging government funding for research, which is a common practice in the industry.

Comparison to Industry Standards

• The Phase 3 HONOR study results, while showing nominal improvement at week 4, did not meet the primary endpoint at week 12, which is a common challenge in PTSD drug development.
• Other companies such as Sage Therapeutics and Biohaven have also been developing treatments for PTSD, but with different mechanisms of action.
• The use of sublingual administration for cyclobenzaprine is a unique approach compared to traditional oral formulations, potentially offering faster absorption and reduced side effects.
• The focus on early intervention after trauma, as seen in the OASIS trial, is a growing area of interest in PTSD research, with other companies also exploring similar strategies.

Stakeholder Impact

• Shareholders may react to the mixed results of the Phase 3 trial and the potential of the upcoming OASIS trial.
• Employees may be impacted by the progress of the clinical trials and the NDA submission.
• Patients with PTSD and fibromyalgia may benefit from the development of TNX-102 SL.
• The company's suppliers and creditors may be impacted by the company's financial performance and the progress of its product development.

Next Steps

• The company will begin enrolling patients in the OASIS trial in the second quarter.
• The company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in the second half of 2024 for Tonmya for the management of fibromyalgia.

Key Dates

Keywords

TNX-102 SL, PTSD, Posttraumatic Stress Disorder, Fibromyalgia, Clinical Trial, Cyclobenzaprine, OASIS Trial, Acute Stress Reaction, Sleep Quality, NDA, Department of Defense, Tonmya